Skip to main content

Table 5 PSA results (ref. Standard care)

From: Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study

Strategy Cost Δ Cost QALY Δ QALY ICER
Standard Care 33371.7   0.7677   
Dexamethasone 33555.6 183.9 0.8028 0.0352 5229.1
Remedesivir 32388.4 -983.3 0.7736 0.0059 Dominant
Rem + Dex 32572.2 -799.4 0.8087 0.0411 Dominant